Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 2
1948 2
1950 1
1952 1
1955 1
1957 2
1960 1
1961 4
1962 1
1965 1
1966 1
1968 2
1972 1
1973 1
1980 1
1982 2
1983 1
1984 1
1985 2
1986 1
1987 1
1988 1
1989 1
1993 1
1994 5
1995 1
1996 3
1997 2
1998 3
1999 3
2000 3
2001 4
2002 8
2003 12
2004 5
2005 9
2006 9
2007 9
2008 11
2009 5
2010 10
2011 10
2012 8
2013 12
2014 15
2015 12
2016 16
2017 11
2018 4
2019 10
2020 8
2021 19
2022 17
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Results by year

Filters applied: . Clear all
Page 1
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O; International Breast Cancer Study Group; POSITIVE Trial Collaborators. Partridge AH, et al. N Engl J Med. 2023 May 4;388(18):1645-1656. doi: 10.1056/NEJMoa2212856. N Engl J Med. 2023. PMID: 37133584 Free PMC article. Clinical Trial.
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Marcus R, et al. Among authors: wenger m. N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598. N Engl J Med. 2017. PMID: 28976863 Free article. Clinical Trial.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Goede V, et al. Among authors: wenger m. N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8. N Engl J Med. 2014. PMID: 24401022 Free article. Clinical Trial.
Gain-of-function mutations in ALPK1 cause an NF-κB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome.
Kozycki CT, Kodati S, Huryn L, Wang H, Warner BM, Jani P, Hammoud D, Abu-Asab MS, Jittayasothorn Y, Mattapallil MJ, Tsai WL, Ullah E, Zhou P, Tian X, Soldatos A, Moutsopoulos N, Kao-Hsieh M, Heller T, Cowen EW, Lee CR, Toro C, Kalsi S, Khavandgar Z, Baer A, Beach M, Long Priel D, Nehrebecky M, Rosenzweig S, Romeo T, Deuitch N, Brenchley L, Pelayo E, Zein W, Sen N, Yang AH, Farley G, Sweetser DA, Briere L, Yang J, de Oliveira Poswar F, Schwartz IVD, Silva Alves T, Dusser P, Koné-Paut I, Touitou I, Titah SM, van Hagen PM, van Wijck RTA, van der Spek PJ, Yano H, Benneche A, Apalset EM, Jansson RW, Caspi RR, Kuhns DB, Gadina M, Takada H, Ida H, Nishikomori R, Verrecchia E, Sangiorgi E, Manna R, Brooks BP, Sobrin L, Hufnagel RB, Beck D, Shao F, Ombrello AK, Aksentijevich I, Kastner DL; Undiagnosed Diseases Network. Kozycki CT, et al. Ann Rheum Dis. 2022 Oct;81(10):1453-1464. doi: 10.1136/annrheumdis-2022-222629. Epub 2022 Jul 22. Ann Rheum Dis. 2022. PMID: 35868845 Free PMC article.
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J. Morschhauser F, et al. Among authors: wenger m. Lancet Haematol. 2019 May;6(5):e254-e265. doi: 10.1016/S2352-3026(19)30026-2. Epub 2019 Mar 29. Lancet Haematol. 2019. PMID: 30935953 Clinical Trial.
[Basics of Denosumab-Therapy aftercare].
Oser S, Wenger M. Oser S, et al. Among authors: wenger m. Praxis (Bern 1994). 2023 Jul;112(9):483-486. Praxis (Bern 1994). 2023. PMID: 37632427 German.
Adjacent-segment morbidity.
Markwalder TM, Wenger M. Markwalder TM, et al. Among authors: wenger m. J Neurosurg. 2002 Jan;96(1 Suppl):139-40. doi: 10.3171/spi.2002.96.1.0139. J Neurosurg. 2002. PMID: 11795706 No abstract available.
Endocrine hypertension in small animals.
Reusch CE, Schellenberg S, Wenger M. Reusch CE, et al. Among authors: wenger m. Vet Clin North Am Small Anim Pract. 2010 Mar;40(2):335-52. doi: 10.1016/j.cvsm.2009.10.005. Vet Clin North Am Small Anim Pract. 2010. PMID: 20219493 Review.
271 results